Revvity (NYSE:RVTY) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Revvity (NYSE:RVTY) from a buy rating to a hold rating in a research report report published on Sunday morning.

A number of other research firms have also recently issued reports on RVTY. Evercore restated an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. Barclays upped their price target on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Wolfe Research began coverage on shares of Revvity in a report on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Weiss Ratings upgraded shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Finally, Stifel Nicolaus reduced their price objective on Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $108.36.

Revvity Stock Down 1.9%

NYSE:RVTY opened at $113.99 on Friday. The stock has a 50-day simple moving average of $110.13 and a 200 day simple moving average of $100.02. Revvity has a 52-week low of $81.22 and a 52-week high of $118.34. The company has a market cap of $12.72 billion, a PE ratio of 54.28, a PEG ratio of 2.13 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.20. The firm had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company’s revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts expect that Revvity will post 5.36 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio (DPR) is 13.33%.

Institutional Investors Weigh In On Revvity

Several institutional investors and hedge funds have recently added to or reduced their stakes in RVTY. Ascentis Independent Advisors bought a new position in shares of Revvity in the 1st quarter valued at $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity in the second quarter valued at about $32,000. MUFG Securities EMEA plc acquired a new stake in Revvity in the second quarter valued at about $34,000. SJS Investment Consulting Inc. boosted its stake in Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after buying an additional 521 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in Revvity in the second quarter valued at about $49,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.